亞洲金融(00662.HK)年度股東應占溢利3.47億港元 同比增加181.5%
格隆匯3月27日丨亞洲金融(00662.HK)宣佈,截至2023年12月31日止年度,公司保險收益達24.56億港元,上年同期為20.6億港元;集團錄得年度股東應占溢利港幣3.47億元,較上年同期增加181.5%。增長由多項關鍵因素驅動,包括股票買賣投資的出色表現及盈利按年取得增長,保險業務業績令人滿意(部分受惠於有關保險合約新會計準則HKFRS17的應用),大部分合資公司及聯營公司也取得穩定回報。
2023年集團的每股盈利為港幣37.2仙。董事會已在2023年8月宣佈派發中期股息每股港幣4.0仙,並建議派發年度末期股息每股港幣5.0仙,因此全年派息總額為每股港幣9.0仙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.